Duopharma Biotech Bhd
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as ca… Read more
Duopharma Biotech Bhd (7148) - Net Assets
Latest net assets as of December 2025: RM757.62 Million MYR
Based on the latest financial reports, Duopharma Biotech Bhd (7148) has net assets worth RM757.62 Million MYR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM1.45 Billion) and total liabilities (RM690.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM757.62 Million |
| % of Total Assets | 52.31% |
| Annual Growth Rate | 9.07% |
| 5-Year Change | 21.41% |
| 10-Year Change | 66.69% |
| Growth Volatility | 29.57 |
Duopharma Biotech Bhd - Net Assets Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual net assets of Duopharma Biotech Bhd from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | RM757.62 Million | +6.84% |
| 2024-12-31 | RM709.15 Million | +3.21% |
| 2023-12-31 | RM687.12 Million | +4.87% |
| 2022-12-31 | RM655.22 Million | +5.00% |
| 2021-12-31 | RM624.00 Million | -3.08% |
| 2020-12-31 | RM643.82 Million | +21.53% |
| 2019-12-31 | RM529.75 Million | +10.13% |
| 2018-12-31 | RM481.04 Million | +0.25% |
| 2017-12-31 | RM479.87 Million | +5.58% |
| 2016-12-31 | RM454.52 Million | +1.07% |
| 2015-12-31 | RM449.72 Million | +132.26% |
| 2014-12-31 | RM193.63 Million | +6.01% |
| 2013-12-31 | RM182.65 Million | +7.12% |
| 2012-12-31 | RM170.50 Million | +3.68% |
| 2011-12-31 | RM164.44 Million | +4.17% |
| 2010-12-31 | RM157.87 Million | +10.60% |
| 2009-12-31 | RM142.74 Million | +9.33% |
| 2008-12-31 | RM130.55 Million | +14.31% |
| 2007-12-31 | RM114.21 Million | -21.47% |
| 2006-12-31 | RM145.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Duopharma Biotech Bhd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 546.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM408.57 Million | 53.93% |
| Common Stock | RM432.47 Million | 57.08% |
| Other Comprehensive Income | RM-83.41 Million | -11.01% |
| Total Equity | RM757.62 Million | 100.00% |
Duopharma Biotech Bhd Competitors by Market Cap
The table below lists competitors of Duopharma Biotech Bhd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grand Fortune Securities Co Ltd
TWO:6026
|
$132.94 Million |
|
Nex Point Public Company Limited
BK:NEX
|
$132.97 Million |
|
AC Immune Ltd
NASDAQ:ACIU
|
$133.04 Million |
|
7707
TWO:7707
|
$133.06 Million |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
$132.90 Million |
|
Varia US Properties AG
LSE:0RKW
|
$132.88 Million |
|
Acme United Corporation
NYSE MKT:ACU
|
$132.86 Million |
|
CHC Resources Corp
TW:9930
|
$132.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Duopharma Biotech Bhd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 709,152,000 to 757,623,000, a change of 48,471,000 (6.8%).
- Net income of 87,463,000 contributed positively to equity growth.
- Dividend payments of 33,668,000 reduced retained earnings.
- Other comprehensive income decreased equity by 5,319,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM87.46 Million | +11.54% |
| Dividends Paid | RM33.67 Million | -4.44% |
| Other Comprehensive Income | RM-5.32 Million | -0.7% |
| Other Changes | RM-5.00K | -0.0% |
| Total Change | RM- | 6.84% |
Book Value vs Market Value Analysis
This analysis compares Duopharma Biotech Bhd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.33x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | RM0.25 | RM1.33 | x |
| 2007-12-31 | RM0.20 | RM1.33 | x |
| 2008-12-31 | RM0.22 | RM1.33 | x |
| 2009-12-31 | RM0.24 | RM1.33 | x |
| 2010-12-31 | RM0.27 | RM1.33 | x |
| 2011-12-31 | RM0.28 | RM1.33 | x |
| 2012-12-31 | RM0.29 | RM1.33 | x |
| 2013-12-31 | RM0.31 | RM1.33 | x |
| 2014-12-31 | RM0.33 | RM1.33 | x |
| 2015-12-31 | RM0.52 | RM1.33 | x |
| 2016-12-31 | RM0.52 | RM1.33 | x |
| 2017-12-31 | RM0.55 | RM1.33 | x |
| 2018-12-31 | RM0.55 | RM1.33 | x |
| 2019-12-31 | RM0.59 | RM1.33 | x |
| 2020-12-31 | RM0.70 | RM1.33 | x |
| 2021-12-31 | RM0.67 | RM1.33 | x |
| 2022-12-31 | RM0.69 | RM1.33 | x |
| 2023-12-31 | RM0.72 | RM1.33 | x |
| 2024-12-31 | RM0.74 | RM1.33 | x |
| 2025-12-31 | RM0.79 | RM1.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Duopharma Biotech Bhd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.54%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.39%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.91x
- Recent ROE (11.54%) is below the historical average (13.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 19.93% | 27.57% | 0.66x | 1.09x | RM14.44 Million |
| 2007 | 28.06% | 27.73% | 0.91x | 1.11x | RM20.62 Million |
| 2008 | 20.99% | 22.30% | 0.82x | 1.15x | RM14.35 Million |
| 2009 | 21.18% | 24.43% | 0.71x | 1.21x | RM15.96 Million |
| 2010 | 18.16% | 21.81% | 0.67x | 1.24x | RM12.88 Million |
| 2011 | 16.24% | 19.33% | 0.70x | 1.20x | RM10.26 Million |
| 2012 | 15.26% | 19.23% | 0.68x | 1.16x | RM8.96 Million |
| 2013 | 17.67% | 19.87% | 0.79x | 1.13x | RM14.01 Million |
| 2014 | 18.22% | 19.93% | 0.80x | 1.15x | RM15.91 Million |
| 2015 | 8.09% | 13.49% | 0.43x | 1.41x | RM-8.58 Million |
| 2016 | 5.90% | 8.57% | 0.47x | 1.46x | RM-18.63 Million |
| 2017 | 8.85% | 9.07% | 0.66x | 1.47x | RM-5.52 Million |
| 2018 | 9.90% | 9.55% | 0.60x | 1.74x | RM-463.10K |
| 2019 | 10.43% | 9.59% | 0.63x | 1.74x | RM2.30 Million |
| 2020 | 9.10% | 10.28% | 0.54x | 1.64x | RM-5.77 Million |
| 2021 | 10.53% | 10.28% | 0.55x | 1.87x | RM3.28 Million |
| 2022 | 10.70% | 10.06% | 0.57x | 1.86x | RM4.59 Million |
| 2023 | 7.66% | 7.47% | 0.52x | 1.96x | RM-16.07 Million |
| 2024 | 8.83% | 7.70% | 0.59x | 1.94x | RM-8.27 Million |
| 2025 | 11.54% | 9.39% | 0.64x | 1.91x | RM11.70 Million |
Industry Comparison
This section compares Duopharma Biotech Bhd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $166,702,295
- Average return on equity (ROE) among peers: 10.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Duopharma Biotech Bhd (7148) | RM757.62 Million | 19.93% | 0.91x | $132.90 Million |
| Kotra Industries Bhd (0002) | $65.03 Million | 15.36% | 0.20x | $23.04 Million |
| PeterLabs Holdings Bhd (0171) | $45.74 Million | 8.76% | 0.51x | $3.70 Million |
| Rhone Ma Holdings Bhd (5278) | $160.98 Million | 7.50% | 0.43x | $4.26 Million |
| YSP Southeast Asia Holding Bhd (7178) | $395.06 Million | 9.45% | 0.32x | $21.44 Million |